Schering-Plough Coricidin repositioning targets hypertension concerns with decongestants.
This article was originally published in The Tan Sheet
Executive Summary
CORICIDIN COUGH/COLD LINE REPOSITIONING TARGETS HYPERTENSION CONCERNS by highlighting the fact three of the products do not contain decongestant ingredients such as pseudoephedrine/ephedrine, phenylephrine and phenylpropanolamine that may cause problems for those with high blood pressure or interfere with medication for the condition. Schering-Plough has repackaged its Coricidin Cold & Flu Tablets, Cold & Cough Tablets and NightTime Cold & Cough Liquid and renamed the line Coricidin HBP. The products are expected to reach stores by the end of January.